Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate vs Amitriptyline in Migraine Prophylaxis
NCT00210821Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Feb 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of topiramate in migraine (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Change from baseline in the average monthly migraine episode rate at 26 weeks. Started Feb 2004; status: completed.
02
Drugs
topiramate
03
Conditions
migraine
Beyond the preview
Go deeper on NCT00210821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210821.